AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is unchanged from the same period last year. The company reported quarterly sales of $8.315 million which beat the analyst consensus estimate of $5.856 million by 41.99 percent. This is a 96.34 percent increase over sales of $4.235 million the same period last year.